Hepatitis B News and Research

Latest Hepatitis B News and Research

New treatment option for patients with most difficult-to-treat forms of hepatitis C

A novel single-pill combination drug could present a new treatment option for patients with the most difficult-to-treat forms of hepatitis C, according to the results of a Phase 2 trial, published in The Lancet.

6 Nov 2013

AGA publishes HCV Clinical Decision Tool for management of HCV-positive patients

The American Gastroenterological Association Clinical Decision Tool for the Screening and Evaluation of Hepatitis C will help gastroenterologists in the early management of HCV-positive patients, according to a new paper in Gastroenterology, the official journal of the American Gastroenterological Association. Chronic HCV has a significant impact on the adult population and is a disease for which much progress has been made in its treatment.

6 Nov 2013

AMGA honors Mid-Atlantic Permanente Medical Group with Acclaim Award

The Mid-Atlantic Permanente Medical Group is the Honoree the American Medical Group Association's Acclaim Award.

6 Nov 2013

Pivotal Phase III STARTVerso data shows efficacy of faldaprevir in genotype-1 infected HCV patients

Boehringer Ingelheim today announced new data from its Phase III clinical trial programme, STARTVerso, which evaluates faldaprevir in combination with pegylated interferon and ribavirin (PegIFN/RBV).

5 Nov 2013

Boehringer Ingelheim's Phase II trial of interferon-free hepatitis C treatment shows promising results

Interim data presented today show that all patients (13/13) who reached their 4-week post-treatment follow-up have undetectable levels of hepatitis C virus (SVR4) after completing a 12-week regimen of faldaprevir, deleobuvir, PPI-668 and ribavirin.

4 Nov 2013

Scientists make seminal breakthrough in understanding molecular basis of bile duct cancer

A team of scientists from the National Cancer Centre Singapore, Duke-NUS Graduate Medical School Singapore, Fundeni Clinical Institute (Romania) and Koen Kaen University (Thailand), have made a seminal breakthrough in understanding the molecular basis of bile duct cancer or cholangiocarcinoma, a rare but highly lethal form of liver cancer.

4 Nov 2013

Infants who get hepatitis C from mothers during childbirth may inherit viral strain

Infants who get hepatitis C from their mothers during childbirth may inherit a viral strain that replicates more quickly than strains found in non-pregnant hosts, according to a new study published Oct. 27 in Nature Medicine.

29 Oct 2013

UHN, Boehringer Ingelheim partner to improve care, education and support for hepatitis C patients

In a move to address a significant unmet need in hepatitis C in Canada, the University Health Network, together with Boehringer Ingelheim (Canada) Ltd., announced today a multi-year partnership that aims to improve care, education and support for patients with hepatitis C. The program, known as Link-C, aims to improve access to hepatitis C care and treatment in remote areas of Ontario and other parts of Canada.

23 Oct 2013

FDA grants Breakthrough Therapy designation to MK-5172/MK-8742 for chronic HCV infection

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration has granted MK-5172/MK-8742 Breakthrough Therapy designation for treatment of chronic hepatitis C virus infection.

23 Oct 2013

Three cups of coffee per day reduce liver cancer risk by more than 50%

Coffee consumption reduces risk of hepatocellular carcinoma (HCC), the most common type of liver cancer, by about 40 percent, according to an up-to-date meta-analysis published in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association.

23 Oct 2013

Sydney researchers plan to introduce rapid HIV and STI testing in pharmacies, dental surgeries

University of Sydney researchers are currently surveying community pharmacists and dentists to gauge their support to introduce rapid HIV and STI testing in pharmacies and dental surgeries, potentially increasing rates of early diagnosis.

22 Oct 2013

FDA approves SC formulation of Genentech's Actemra for rheumatoid arthritis

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration has approved a subcutaneous formulation of Actemra (tocilizumab) for the treatment of adults with moderately to severely active rheumatoid arthritis who have used one or more disease-modifying antirheumatic drugs, such as methotrexate, that did not provide enough relief.

22 Oct 2013

UCLA receives $7M grant to investigate links between substance abuse and HIV among minority men

The National Institute on Drug Abuse has awarded UCLA a $7 million grant to investigate the links between substance abuse and HIV among Latino and African-American men who have sex with men.

22 Oct 2013

Medmira Wins Additional $1.9M Army Contract

...

21 Oct 2013

Inovio Pharmaceuticals begins phase I clinical trial for hepatitis C vaccine

Inovio Pharmaceuticals, Inc. announced today that the safety, tolerability and immunogenicity of its therapeutic vaccine for hepatitis C (INO-8000/VGX-6150) will be studied in a phase I clinical trial in chronically HCV infected patients.

21 Oct 2013

Medivir announces data from phase III studies of simeprevir in patients co-infected with HCV genotype-1 and HIV-1

Medivir AB (OMX:MVIR-B) today announced preliminary data from two phase III studies conducted by Janssen R&D Ireland evaluating simeprevir in genotype 4 chronic hepatitis C in adult patients with compensated liver disease, and in genotype 1 hepatitis C and HIV-1 co-infected adult patients.

19 Oct 2013

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

UCB announced today that the U.S. Food and Drug Administration has approved Cimzia (certolizumab pegol) for the treatment of adults with active ankylosing spondylitis.

18 Oct 2013

HBV-infected men more likely to develop liver cancer

A team of researchers has identified a novel mutation in the hepatitis B virus (HBV) in Korea that appears only in men and could help explain why HBV-infected men are roughly five times more likely than HBV-infected women to develop liver cancer.

18 Oct 2013

Janssen seeks European marketing approval for combination of once-daily darunavir with cobicistat

Janssen-Cilag International NV, today announced it has submitted a Marketing Authorisation Application to the European Medicines Agency seeking approval for a once-daily single tablet fixed-dose antiretroviral combination product containing darunavir, a protease inhibitor developed by Janssen, with cobicistat, a pharmacokinetic enhancer or boosting agent, developed by Gilead Sciences, Inc. for use in combination with other human immunodeficiency virus medicines.

15 Oct 2013

Researchers find ways to identify, isolate HCC progenitor cells before tumors become evident

For the first time, researchers at the University of California, San Diego School of Medicine have isolated and characterized the progenitor cells that eventually give rise to malignant hepatocellular carcinoma tumors - the most common form of liver cancer. The researchers found ways to identify and isolate the HCC progenitor cells long before actual tumors were apparent.

11 Oct 2013

Hepatitis B News and Research

Latest Hepatitis B News and Research

New treatment option for patients with most difficult-to-treat forms of hepatitis C

AGA publishes HCV Clinical Decision Tool for management of HCV-positive patients

AMGA honors Mid-Atlantic Permanente Medical Group with Acclaim Award

Pivotal Phase III STARTVerso data shows efficacy of faldaprevir in genotype-1 infected HCV patients

Boehringer Ingelheim's Phase II trial of interferon-free hepatitis C treatment shows promising results

Scientists make seminal breakthrough in understanding molecular basis of bile duct cancer

Infants who get hepatitis C from mothers during childbirth may inherit viral strain

UHN, Boehringer Ingelheim partner to improve care, education and support for hepatitis C patients

FDA grants Breakthrough Therapy designation to MK-5172/MK-8742 for chronic HCV infection

Three cups of coffee per day reduce liver cancer risk by more than 50%

Sydney researchers plan to introduce rapid HIV and STI testing in pharmacies, dental surgeries

FDA approves SC formulation of Genentech's Actemra for rheumatoid arthritis

UCLA receives $7M grant to investigate links between substance abuse and HIV among minority men

Medmira Wins Additional $1.9M Army Contract

Inovio Pharmaceuticals begins phase I clinical trial for hepatitis C vaccine

Medivir announces data from phase III studies of simeprevir in patients co-infected with HCV genotype-1 and HIV-1

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

HBV-infected men more likely to develop liver cancer

Janssen seeks European marketing approval for combination of once-daily darunavir with cobicistat

Researchers find ways to identify, isolate HCC progenitor cells before tumors become evident

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Hepatitis B News and Research

Latest Hepatitis B News and Research

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Newsletters you may be interested in